Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

An ultra-rare kidney disease that can become life-threatening now has its first FDA ... the drug expanded its approval to include the rare autoimmune kidney disease IgA nephropathy. Novartis ...

Novartis NVS obtains FDA approval of atrasentan, a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy ...

Novartis (NYSE:NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as ... which plays a role in kidney disease progression. By doing so, it helps reduce proteinuria ...

Also Read: FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ... with previously reported data. This is Novartis’s third U.S. approval for its kidney disease portfolio in the last ...

The FDA approved Novartis' Fabhalta, making it the first and only treatment for adults with C3 glomerulopathy. Fabhalta showed sustained proteinuria reduction in Phase 3 trials, with effects seen ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis ... This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of ... C3G is a progressive and ultra-rare kidney ...